Skip to main content
. 2001 Jan 30;98(3):1206–1211. doi: 10.1073/pnas.98.3.1206

Figure 2.

Figure 2

Summary of therapy results obtained with the cardiac-puncture administration of 64Cu-ATSM in hamsters bearing the GW39 carcinoma. Endpoint was 135 days or a tumor burden of 10 g, whichever came first. (A) Therapy of 7-day-old GW39 tumors in hamsters. Single administration of saline and hydralazine (♦, n = 10), 10 mCi of 64Cu-ATSM without hydralazine (■, n = 10), or 10 mCi of 64Cu-ATSM with hydralazine pretreatment (▴, n = 9). (B) Therapy of 7-day-old GW39 tumors in hamsters by using dose fractionation. Administration of saline, (♦, n = 10), 3 × 4 mCi of 64Cu-ATSM at 72-h intervals without hydralazine (■, n = 13), or 3 × 4 mCi of 64Cu-ATSM at 72-h intervals with hydralazine pretreatment (▴, n = 13). (C) Therapy of 7-day-old GW39 tumors in hamsters. Comparison of 10 (▴, n = 10), 8 (■, n = 11), and 6 (♦, n = 12) mCi. (D) Therapy of 15-day-old GW39 tumors in hamsters. Comparison of 4 (♦, n = 7), 6 (●, n = 9), 7 (⋄, n = 9), 8 (▵, n = 9), and 10 (▴, n = 10) mCi.